The physiological function of prion proteins (PrP) remains unclear. To investigate the physiological relevance of PrP, we constructed a fusion protein of PrP with enhanced blue fluorescent protein (PrP-EBFP) to quantify the interaction of PrP with other molecules. Production of soluble PrP-EBFP was achieved by lowering the expression temperature in Escherichia coli (E. coli) cells to 15 C. Soluble PrP-EBFP was purified on cation exchange and heparin-affinity columns to yield high purity protein. This is the first report of the preparation of soluble recombinant PrP without refolding following solubilization using denaturants or disruption using detergents. To confirm the integrity of PrP-EBFP, anisotropy was estimated under physiological conditions in the presence of heparin, which interacts with PrP. The dissociation constant was determined to be 0:88 AE 0:07 M. PrP-EBFP should be useful in the quantification of PrP interactions with other molecules.
The mature prion protein (PrP) is composed of approximately 210 amino acid residues after removal of the N-terminus, a signal sequence for subcellular localization, and the C-terminal signal sequence, the site of attachment of a glycosylphosphatidylinositol (GPI) anchor. 1) PrP is normally attached to the plasma membrane via the C-terminal GPI-anchor. 2) According to NMR studies, the N-terminal portion of PrP contains a flexible extended region, while the C-terminal domain forms a globule fold including three -helices and a small flexible -sheet. [3] [4] [5] In in vivo experiments, PrP has been found to participate in signal transduction, 6) copper metabolism, 7) and the regulation of acetylcholine release. 8) In in vitro experiments, PrP influenced superoxide dismutase activity 9) and interacted with copper, 7) B-crystalline, 10) and heparan.
11) The precise physiological function of PrP, however, remains unclear. To investigate the in vivo role of PrP, it is important to quantify the interactions of PrP with other molecules. It has been difficult, however, to produce recombinant PrP in soluble form without artificial manipulation, such as refolding following a solubilization using denaturants or disruption using high concentrations of detergents, techniques that can alter the integrity of PrP.
In this study, we constructed a fusion protein of EBFP linked to the C-terminus of PrP (PrP-EBFP) as a tool to detect PrP interactions with other molecules.
Materials and Methods
Construction of expression vectors. A clone (#761999) encoding mouse PrP (mPrP) cDNA (GenBank accession no. AB23544) was the kind gift of the consortium, Integrated Molecular Analysis of Genomes and their Expression. A mPrP cDNA encoding the mature region from residues 23 to 231 was amplified using the clone as template, a forward primer, 5 0 -GCT GCT AGC AAA AAG CGG CCA AAG CCT GG-3 0 , and a reverse primer, 5 0 -CGA GCT AGC TAG GCT GGA TCT TCT CCC GTC GT-3 0 (NheI sites underlined). To construct a PrP-EBFP-expression vector, pQBI67-PrP, the NheI-treated PrP-fragment was inserted into pQBI67 (Wako Chemicals, Osaka, Japan). The DNA sequence and direction of mPrP cDNA were confirmed using a genetic analyzer (ABI310, Applied Biosystems, Foster City, CA).
Expression and cell disruption. PrP-EBFP was produced in Escherichia coli (E. coli) cells, BL21(DE3), harboring pQBI67-PrP in LB medium containing 100 mg/ml ampicillin by the addition of 0.1 mM isopropylthiogalactopyranoside (IPTG) at 37 C for 13 h or at * These authors contributed equally to this work. 15 C for 20 h. Collected cells were resuspended in lysis buffer (20 mM Tris-HCl, 20 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, PMSF, pH 7.5), and disrupted using a sonicator (UD-200, TOMY, Tokyo). Samples were separated into soluble and insoluble fractions by centrifugation at 14;000 Â g at 4 C for 20 min. Proteins were separated by 10% SDS-PAGE, and then stained with 0.25% Coomassie Brilliant Blue R-250, 12) or were visualized by western blotting 13) using mPrP-specific antiserum produced in rabbits.
Purification of PrP-EBFP. Soluble proteins were applied to a cation exchange column (Hitrap SP HP, GE Healthcare, Boston, MA) and then eluted with a linear 0.02 to 1.0 M NaCl gradient of Tris-buffer (20 mM TrisHCl, 1 mM EDTA, and 1 mM PMSF, pH 7.5). PrP-EBFP peak fractions were diluted in 2 volumes of Tris-buffer. The sample was applied to a heparin-affinity column (HiTrap Heparin HP, GE Healthcare), and then eluted in the same way. The protein concentration was estimated by the UV absorption at 386 nm using a molecular extinction coefficient of 16,500.
14)
Fluorescence anisotropy measurements of PrP-EBFP. The fluorescence intensity of 0.2 mM of purified PrP-EBFP in the presence of varying concentrations of heparin (Wako Chemicals) was measured in 50 mM Tris-HCl and 20 mM NaCl, pH 7.5, at 25 C on a fluorescence spectrophotometer (model F-2500, Hitachi, Tokyo) with excitation at 386 nm using polarizers. The steady anisotropy, r, was calculated from
where
where I represents the relative fluorescence intensity at the emission maximum wavelength of 450 nm, the twoletter subscript refers to the vertical (V) and horizontal (H) positions of the excitation and emission polarizers respectively, and G is a value that depends on the detection system. 15) These data represent the averages of three independent experiments. The dissociation constant was estimated by fitting equation 7 (see ''Results'' below) to the data using KaleidaGraph software (Synergy Software, Reading, PA) with heparin M W ¼ 15;000.
Results
Production and purification of a soluble PrP-EBFP PrP-EBFP was produced in E. coli cells harboring pQBI67-PrP at 37 C or 15 C by the addition of IPTG (Fig. 1) . The theoretical molecular mass of PrP-EBFP is 50.1 kDa, which is the sum of the molecular weights of mPrP (23.0 kDa) and EBFP (27.1 kDa). After cell disruption, the liberated proteins were separated into soluble and insoluble fractions by centrifugation. The PrP-EBFP produced at 37 C was localized almost exclusively in the insoluble fraction (Fig. 1A, lanes 3  and 6) . In contrast, the PrP-EBFP produced at 15 C was largely soluble (Fig. 1B, lanes 2 and 5) . These results indicate that PrP-EBFP can be produced in a soluble form by lowering the expression temperature.
To purify soluble PrP-EBFP, cells expressing PrP-EBFP at 15 C were collected from 2 liters of the culture. After suspension of the cell pellet in lysis buffer, the cells were disrupted and separated into insoluble and soluble fractions. The soluble fraction was applied to a cation exchange column. Bound proteins were eluted with a linear 0.02 to 1.0 M NaCl gradient in Tris-buffer (Fig. 2, lanes 2 and 5) . After dilution of the collected PrP-EBFP fractions, the proteins were applied to a heparin affinity column. Bound proteins were eluted with the same linear gradient in Tris-buffer (Fig. 2, lanes  3 and 6) . The final amount of PrP-EBFP isolated was approximately 0.7 mg, with a purity of 99%.
Determination of the equilibrium constant of the heparin-PrP-EBFP complex
The fluorescence emission spectrum of PrP-EBFP alone was similar to that of EBFP alone, with an emission maximum at 450 nm (Data not shown). Anisotropy, r, was calculated from equation 1, and the values obtained were expressed as a function of increasing concentrations of heparin (Fig. 3) . Anisotropy data were then used to calculate the fractional saturation of PrP-EBFP: where r obs is the observed anisotropy at a given concentration of heparin, r min is the anisotropy of PrP-EBFP without heparin, and r max is the anisotropy of PrP-EBFP saturated with heparin.
15) The dissociation constant between PrP-EBFP and heparin, K D , is shown below:
in which X, Y, and Z represent heparin, PrP-EBFP, and the heparin-PrP-EBFP complex respectively. Equation 3 is equivalent to 15) f ¼ Z=ðX þ YÞ: ð5Þ
Equations 4 and 5 were combined to give
in which X is PrP-EBFP. Equations 3 and 6 were rearranged to give
The curve-fitting analysis worked well using equation 7 (Fig. 3) . The K D was directly determined to be 0:88 AE 0:07 mM. EBFP anisotropy was not increased following the addition of heparin. EBFP alone did not bind to the heparin affinity column (data not shown). These results indicate that PrP in the context of this fusion protein retains its heparin-binding activity.
Discussion
The flexible N-terminal domain of PrP is essential to its physiological function. 16) Linkage of EBFP to the Nterminus of PrP might interfere with PrP function. Since functional PrP is attached to the cell surface by a Ctermini-linked GPI-anchor, 2) the attachment of EBFP to the C-terminus of PrP should allow expression of the cellular function of PrP. Based on these points, we generated a fusion of EBFP with the C-terminus of PrP. In previous studies, experiments examining PrP function utilized recombinant PrPs refolded after solubilization with urea and guanidine hydrochloride [3] [4] [5] or dissolved in high concentrations of sarcosyl and Triton X-100. 17) Previously, an enhanced green fluorescent protein fused to the C-terminus of PrP (PrP-EGFP) was expressed in E. coli at 37 C in an insoluble form. 18) In this study, we succeeded in producing a soluble PrP-EBFP at a low expression temperature (Fig. 1B) by multi-step purification (Fig. 2) . Lowering the expression temperature has been found to solubilize and improve the activity of insoluble recombinant proteins produced at 37 C. 19) The low temperatures promoted the solubility of PrP-EBFP by favoring the productive folding of PrP-EBFP (Fig. 1B) . This is the first report detailing the production of soluble mature recombinant PrP without artificial manipulation, such as refolding or the addition of detergents.
PrP-EBFP was purified on a heparin affinity column (Fig. 2, lanes 3 and 6) . To confirm the integrity of PrP-EBFP, we assessed the interaction of PrP with heparin by measuring the fluorescence anisotropy of PrP-EBFP (Fig. 3) . Since EBFP alone did not bind the affinity column (data not shown), the binding was PrP-specific. These results indicate that PrP-EBFP retains heparinbinding activity under physiologic conditions. Recently, Proteins in the supernatant fraction (lanes 1 and 4) were applied to a cation exchange column, and then eluted with a linear 0.02 to 1.0 M NaCl gradient of Tris-buffer. PrP-EBFP peak fractions were collected (lanes 2 and 5). The collected proteins were applied to a heparin-affinity column, and then eluted with the same salt linear gradient. Purified proteins were concentrated by centrifugation in a centrifugal filter device (lanes 3 and 6). Proteins were separated by 10% SDS-PAGE and either stained with 0.25% Coomassie Brilliant Blue R-250 (lanes 1-3) or visualized by western blotting using PrPspecific antiserum (lanes 4-6). measurement of the fluorescence polarization of the PrPheparin complex covalently linked to a chemical chromophore, AlexaFluor488, has been reported. 20) Our system, however, is more specific: (a) the effort of labeling the interacting target is unnecessary, (b) as the anisotropy of EBFP is measured, the number and position of the chromophore are fixed, preventing non-specific binding from any irregular linkages of the chromophore, (c) in contrast to other system, an acute sigmoid curve is obtained in our system (Fig. 3) , and (d) the interaction is assessed under physiological pH conditions, while other system entails observing the interaction under acidic pH. This tool, PrP-EBFP, is therefore a useful tool to probe for targets interacting with PrP that allows stoichiometric quantification of PrP interactions.
